News

Higher Medicine Announces Strategic Investment by Cerdwen to Accelerate Therapies for Kabuki Syndrome and Other Brain Disorders

Higher Medicine Inc.  announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation.

Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact.

“Higher Medicine exemplifies the type of company we seek to partner with: rigorous science, a focused initial indication, and a platform capable of expanding into significant unmet medical needs,” said Kevin Brophy, Managing Principal of Cerdwen. “Dr. Kim and his team are tackling complex CNS disorders with a differentiated epigenetic approach, and we believe the company is well-positioned to translate that ambition into clinical impact.”

“Higher Medicine was founded on a simple but ambitious belief: that many devastating brain disorders need not be lifelong sentences,” said Dr. Leo Kim, Founder and CEO of Higher Medicine. “By harnessing epigenetic biology, we aim to prevent, slow, or even reverse conditions that few companies are willing to confront. Our initial focus on Kabuki syndrome is a deliberate entry point into a broader platform that can be extended to multiple high-unmet-need CNS indications such as CTE and Alzheimer’s disease. With Cerdwen’s investment, we will heighten the momentum for the seed round and accelerate toward clinical proof-of-concept.”

“This investment represents a strong validation of Higher Medicine’s scientific vision and execution,” said Marie Mazur, Board Member of the Mid-Atlantic Diamond Venture (MADV). “It also highlights the power of MADV’s regional biotech network and quarterly Forums, as this partnership originated from our December pitch event.”

The investment was completed via a Simple Agreement for Future Equity (SAFE) and closed on December 31, 2025. The transaction advances Higher Medicine’s Seed Expansion financing and marks a key milestone toward first-in-human clinical studies.

Read more here.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these